MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® Sonelokimab in patients with moderate-to-s

ZUG, Switzerland, March 24, 2022 /PRNewswire/ -- MoonLake Immunotherapeutics AG ("MoonLake"), a...

Related Keywords

Switzerland ,United States ,Kristian Reich ,Moonlake Immunotherapeutics ,Prnewswire Moonlake Immunotherapeutics ,Hidradenitis Suppurativa ,Matthias Bodenstedt ,Drug Administration ,Investigational New Drug ,Institutional Review ,Hidradenitis Suppurativa Clinical Response ,Chief Scientific Officer ,Global Assessment Score ,Psoriasis Area ,Severity Index ,Securities Litigation Reform Act ,